Key result
CRISPR-Cas genome editing advances the development of genetic disease therapies and enhances cell therapies.
Why the study?
The CRISPR-Cas genome editing platform has expanded biological research capabilities and has been applied to developing therapies for genetic diseases and enhancing cell therapies.
This review highlights recent advances in the application of CRISPR-Cas genome editing for treating genetic diseases and enhancing cell therapies.
Advances in CRISPR-Cas therapies merit research monitoring but should not yet change practice; leaves open need for clinical validation trials.
The advent of the CRISPR-Cas genome editing platform has greatly enhanced the capabilities of researchers in many areas of biology. Its use has also been turned to the development of therapies for genetic diseases and to the enhancement of cell therapies. This review describes some recent advances in these areas.
No takes yet. Share an insight, caveat, or question.
Dana Carroll (2022) studied this question. CRISPR-Cas genome editing is advancing the development of therapies for genetic diseases and the enhancement of cell therapies.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: